Low-dose isotretinoin does not affect ovarian reserve

 Isotretinoin, one of the most frequently used drugs in routine dermatological practice, has been raised for teratogenicity with a black box warning. The aim of the current study was to evaluate the effect of low-dose isotretinoin on ovarian reserve in women with moderate to severe acne. A 6-month prospective controlled cohort study of 60 female acne patients and 66 controls receiving low-dose isotretinoin. Effects on ovarian reserve were evaluated by anti-Müllerian hormone, ovarian volume, and antral follicle count.


As a result, there was no significant difference in serum anti-Mullerian hormone levels between isotretinoin-treated and control patients. In addition, there was no significant change in anti-Müllerian hormone levels before and after treatment in treated patients. Both ovarian volume and antral follicle number did not change significantly before and after treatment

Comments

Popular posts from this blog

L'Oréal forms research and technology alliance with Israeli climate tech company

"THE SONOKO White Mask" for moisturizing and transparent skin of adults

L'Oreal Research & Innovation, Morishita Jintan Co., Ltd. and L'Oreal's first successful development of cutting-edge "active delivery capsules" made of useful ingredients for plant-derived cosmetics